Search

Your search keyword '"Vilardell, M"' showing total 440 results
Start Over Author "Vilardell, M"
440 results on '"Vilardell, M"'

3. Estudios funcionales de variantes de DKK1 presentes en la población general

Author

Martínez-Gil N, Roca-Ayats N, Vilardell M, Civit S, Urreizti R, García-Giralt N, Mellibovsky L, Nogués X, Díez-Pérez A, Grinberg D, and Balcells S

Subjects
DKK1, estudios funcionales, variantes de cambio de sentido, luciferasa, vía de Wnt, masa ósea elevada, Medicine, Osteopathy, RZ301-397.5
Abstract

Objetivo: En las últimas décadas se han identificado genes asociados a la masa ósea y al riesgo de fractura osteoporótica, varios de los cuales pertenecen a la vía de Wnt. En este proyecto se estudió la funcionalidad de 7 mutaciones de cambio de sentido del gen DKK1 –un inhibidor de la vía de Wnt– presentes en la población general. Material y métodos: Se realizaron estudios in vitro del gen reportero luciferasa para medir la actividad de la vía de Wnt en presencia o ausencia de DKK1 silvestre o mutada, y estudios de western blot, para evaluar si las distintas mutaciones afectan a su síntesis y/o a su estabilidad. Resultados: La proteína DKK1 con la variante p.Ala41Thr presenta menor actividad inhibidora de la vía en comparación con la proteína silvestre. También se observaron diferencias significativas entre los experimentos realizados en ausencia de DKK1 y los que incluyen DKK1 con la mutación p.Ala41Thr. Los western blots mostraron que la cantidad de proteína era similar para todas las variantes, tanto las mutadas como la silvestre, por lo que la pérdida de actividad de p.Ala41Thr no parecía deberse a falta de proteína. El resto de las mutaciones no presentaron un comportamiento diferente al de la proteína DKK1 silvestre. Conclusiones: La variante de cambio de sentido p.Ala41Thr de la proteína DKK1, con una frecuencia poblacional de 0,013%, presenta una pérdida parcial de su función inhibidora, que no es debida a la falta de expresión de ésta. Esta variante génica podría conllevar un aumento de la densidad mineral ósea en las personas de la población general portadoras de esta mutación.

Published
2018
Full Text
View/download PDF

6. Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain

Author

Universitat Rovira i Virgili, Clèries R; Ameijide A; Buxó M; Vilardell M; Martínez JM; Font R; Marcos-Gragera R; Puigdemont M; Viñas G; Carulla M; Espinàs JA; Galceran J; Izquierdo Á; Borràs JM, Universitat Rovira i Virgili, and Clèries R; Ameijide A; Buxó M; Vilardell M; Martínez JM; Font R; Marcos-Gragera R; Puigdemont M; Viñas G; Carulla M; Espinàs JA; Galceran J; Izquierdo Á; Borràs JM

Abstract

Mortality from cardiovascular disease (CVD), second tumours, and other causes is of clinical interest in the long-term follow-up of breast cancer (BC) patients. Using a cohort of BC patients (N = 6758) from the cancer registries of Girona and Tarragona (north-eastern Spain), we studied the 10-year probabilities of death due to BC, other cancers, and CVD according to stage at diagnosis and hormone receptor (HR) status. Among the non-BC causes of death (N = 720), CVD (N = 218) surpassed other cancers (N = 196). The BC cohort presented a significantly higher risk of death due to endometrial and ovarian cancers than the general population. In Stage I, HR− patients showed a 1.72-fold higher probability of all-cause death and a 6.11-fold higher probability of breast cancer death than HR+ patients. In Stages II–III, the probability of CVD death (range 3.11% to 3.86%) surpassed that of other cancers (range 0.54% to 3.11%). In Stage IV patients, the probability of death from any cancer drove the mortality risk. Promoting screening and preventive measures in BC patients are warranted, since long-term control should encompass early detection of second neoplasms, ruling out the possibility of late recurrence. In patients diagnosed in Stages II–III at an older age, surveillance for preventing late cardiotoxicity is crucial.

Published
2023

7. Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective

Author

Herwig, R., Gmuender, H., Corvi, R., Bloch, K. M., Brandenburg, A., Castell, J., Ceelen, L., Chesne, C., Doktorova, T. Y., Jennen, D., Jennings, P., Limonciel, A., Lock, E. A., McMorrow, T., Phrakonkham, P., Radford, R., Slattery, C., Stierum, R., Vilardell, M., Wittenberger, T., Yildirimman, R., Ryan, M., Rogiers, V., and Kleinjans, J.

Published
2016
Full Text
View/download PDF

10. Predicting Ovarian-Cancer Burden in Catalonia by 2030: An Age–Period–Cohort Modelling

Author

Universitat Rovira i Virgili, Peremiquel-Trillas P; Frias-Gomez J; Alemany L; Ameijide A; Vilardell M; Marcos-Gragera R; Paytubi S; Ponce J; Martínez JM; Pineda M; Brunet J; Matías-Guiu X; Carulla M; Galceran J; Izquierdo Á; Borràs JM; Costas L; Clèries R, Universitat Rovira i Virgili, and Peremiquel-Trillas P; Frias-Gomez J; Alemany L; Ameijide A; Vilardell M; Marcos-Gragera R; Paytubi S; Ponce J; Martínez JM; Pineda M; Brunet J; Matías-Guiu X; Carulla M; Galceran J; Izquierdo Á; Borràs JM; Costas L; Clèries R

Abstract

Ovarian cancer is the most lethal gynaecological cancer in very-high-human-developmentindex regions. Ovarian cancer incidence and mortality rates are estimated to globally rise by 2035, although incidence and mortality rates depend on the region and prevalence of the associated risk factors. The aim of this study is to assess changes in incidence and mortality of ovarian cancer in Catalonia by 2030. Bayesian autoregressive age–period–cohort models were used to predict the burden of OC incidence and mortality rates for the 2015–2030 period. Incidence and mortality rates of ovarian cancer are expected to decline in Catalonia by 2030 in women ≥ 45 years of age. A decrease in ovarian-cancer risk was observed with increasing year of birth, with a rebound in women born in the 1980s. A decrease in mortality was observed for the period of diagnosis and period of death. Nevertheless, ovarian-cancer mortality remains higher among older women compared to other age groups. Our study summarizes the most plausible scenario for ovarian-cancer changes in terms of incidence and mortality in Catalonia by 2030, which may be of interest from a public health perspective for policy implementation.

Published
2022

13. Excess mortality among breast cancer patients in early stages in Tarragona and Gerona (Spain) [Exceso de mortalidad en las pacientes con cáncer de mama en estadios precoces en Tarragona y Gerona (España)]

Author

Universitat Rovira i Virgili, Clèries R., Ameijide A., Buxó M., Vilardell M., Martínez J.M., Marcos-Gragera R., Vilardell M.L., Carulla M., Espinàs J.A., Galceran J., Borràs J.M., Izquierdo Á., Universitat Rovira i Virgili, and Clèries R., Ameijide A., Buxó M., Vilardell M., Martínez J.M., Marcos-Gragera R., Vilardell M.L., Carulla M., Espinàs J.A., Galceran J., Borràs J.M., Izquierdo Á.

Abstract

© 2018 SESPAS Objective: To analyze the population-based survival of breast cancer (CM) diagnosed in early stages estimating the time trends of excess mortality (EM) in the long term in annual and five-year time intervals, and to determine, if possible, a proportion of patients who can be considered cured. Method: We included women diagnosed with BC under the age of 60 years in stages I and II in Girona and Tarragona (N = 2453). The observed (OS) and relative survival (RS) were calculated up to 20 years of follow-up. RS was also estimated at annual (RSI) and in five-year intervals (RS5) to graphically assess the EM. The results are presented by age groups (≤49 and 50-59), stage (I/II) and diagnostic period (1985-1994 and 1995-2004). Results: In stage I, OS and RS were higher during 1995-2004 compared to 1985-1994: 3.5% at 15 years of follow-up and 4.5% at 20-years of follow-up. In 1995-2004, the OS surpassed 80% in stage I patients whereas in stage II it remained below 70%. During 1995-2004, the long-term EM did not level off towards 0 (RSI <1) independently of age group, stage and period of diagnosis. After 15 years of follow-up, the 5-year EM oscillated between 1 and 5% in stage I (RS5 ≥0.95) and between 5 and 10% in stage II. Conclusions: In our cohort, after 15 years of follow-up, it was detected that the annual EM did not disappear and the five-year EM remained between 1 and 10%. Therefore, it was not possible to determine a cure rate of BC during the study period.

Published
2020

21. Functional studies of DKK1 variants present in the general population

Author

Martínez-Gil, N, Roca-Ayats, N, Vilardell, M, Civit, S, Urreizti, R, García-Giralt, N, Mellibovsky, L, Nogués, X, Díez-Pérez, A, Grinberg, D, and Balcells, S

Subjects
musculoskeletal diseases, vía de Wnt, DKK1, masa ósea elevada, missense variants, luciferasa, functional studies, Wnt pathway, High Bone Mass (HBM), luciferase, variantes de cambio de sentido, osteoporosis, estudios funcionales
Abstract

Resumen Objetivos: En las últimas décadas se han identificado genes asociados a la masa ósea y al riesgo de fractura osteoporótica, varios de los cuales pertenecen a la vía de Wnt. En este proyecto se estudió la funcionalidad de 7 mutaciones de cambio de sentido del gen DKK1 –un inhibidor de la vía de Wnt– presentes en la población general. Material y métodos: Se realizaron estudios in vitro del gen reportero luciferasa para medir la actividad de la vía de Wnt en presencia o ausencia de DKK1 silvestre o mutada, y estudios de western blot, para evaluar si las distintas mutaciones afectan a su síntesis y/o a su estabilidad. Resultados: La proteína DKK1 con la variante p.Ala41Thr presenta menor actividad inhibidora de la vía en comparación con la proteína silvestre. También se observaron diferencias significativas entre los experimentos realizados en ausencia de DKK1 y los que incluyen DKK1 con la mutación p.Ala41Thr. Los western blots mostraron que la cantidad de proteína era similar para todas las variantes, tanto las mutadas como la silvestre, por lo que la pérdida de actividad de p.Ala41Thr no parecía deberse a falta de proteína. El resto de las mutaciones no presentaron un comportamiento diferente al de la proteína DKK1 silvestre. Conclusiones: La variante de cambio de sentido p.Ala41Thr de la proteína DKK1, con una frecuencia poblacional de 0,013%, presenta una pérdida parcial de su función inhibidora, que no es debida a la falta de expresión de ésta. Esta variante génica podría conllevar un aumento de la densidad mineral ósea en las personas de la población general portadoras de esta mutación. Abstract Objectives: In recent decades, genes associated with bone mass and osteoporotic fracture risk have been identified, several of which belong to the Wnt pathway. In this project, the functionality of 7 missense mutations of the gene DKK1 –an inhibitor of the Wnt pathway– present in the general population was studied. Materials and methods: In vitro studies of the luciferase reporter gene were carried out to measure Wnt pathway activity in the presence or absence of wild-type or mutated DKK1, and western blot studies, to evaluate if the different mutations affect its synthesis and/or stability. Results: The DKK1 protein with the p.Ala41Thr variant shows lower pathway inhibitory activity compared to the wild-type protein. Significant differences were also observed between the experiments performed in the absence of DKK1 and those that include DKK1 with the p.Ala41Thr mutation. Western blots showed that the amount of protein was similar for all variants, both mutated and "wild-type, so the loss of p.Ala41Thr activity did not seem to be due to a lack of protein. The rest of the mutations did not show different behavior from that of the wild DKK1 protein. Conclusions: The missense variant p.Ala41Thr of the DKK1 protein, with a population frequency of 0.013%, shows a partial loss of its inhibitory function, which is not due to the lack of expression. This gene variant could lead to an increase in bone mineral density in those people in the general population who carry this mutation.

Published
2018

24. GCAT vertical bar Genomes for life: a prospective cohort study of the genomes of Catalonia

Author

Obon-Santacana, M, Vilardell, M, Carreras, A, Duran, X, Velasco, J, Galvan-Femenia, I, Alonso, T, Puig, L, Sumoy, L, Duell, EJ, Perucho, M, Moreno, V, and de Cid, R

Abstract

Purpose The prevalence of chronic non-communicable diseases (NCDs) is increasing worldwide. NCDs are the leading cause of both morbidity and mortality, and it is estimated that by 2030, they will be responsible for 80% of deaths across the world. The Genomes for Life (GCAT) project is a long-term prospective cohort study that was designed to integrate and assess the role of epidemiological, genomic and epigenomic factors in the development of major chronic diseases in Catalonia, a north-east region of Spain. Participants At the end of 2017, the GCAT Study will have recruited 20 000 participants aged 40-65 years. Participants who agreed to take part in the study completed a self-administered computer-driven questionnaire, and underwent blood pressure, cardiac frequency and anthropometry measurements. For each participant, blood plasma, blood serum and white blood cells are collected at baseline. The GCAT Study has access to the electronic health records of the Catalan Public Healthcare System. Participants will he followed biannually at least 20 years after recruitment. Findings to date Among all GCAT participants, 59.2% are women arid 83.3% of the cohort identified themselves as Caucasian/white. More than half of the participants have higher education levels, 72.2% are current workers and 42.1 % are classified as overweight (body mass index >= 25 and

Published
2018

29. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author

Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health

Subjects
Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract

We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009
Full Text
View/download PDF

30. Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly

Author

Clèries, R., primary, Ameijide, A., additional, Marcos-Gragera, R., additional, Pareja, L., additional, Carulla, M., additional, Vilardell, M.-L., additional, Esteban, L., additional, Buxó, M., additional, Espinàs, J.-A., additional, Puigdefàbregas, A., additional, Ribes, J., additional, Izquierdo, A., additional, Galceran, J., additional, and Borrás, J. M., additional

Published
2017
Full Text
View/download PDF

32. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study

Author

Sánchez-Montalvá A, Fernández-Luque A, Cp, Simeón, Fonollosa-Plà V, Marín A, Guillén A, and Vilardell M

Subjects
Adult, Male, Scleroderma, Systemic, Exosome Multienzyme Ribonuclease Complex, Nuclear Proteins, Middle Aged, Ribonucleoproteins, Small Nuclear, Cross-Sectional Studies, DNA Topoisomerases, Type I, Ribonucleoproteins, Spain, Antibodies, Antinuclear, Exoribonucleases, Humans, Female, Aged, Autoantibodies, Retrospective Studies
Abstract

To date, the diagnostic utility of anti-SSA/Ro52 autoantibodies in scleroderma and the association of them with certain clinical manifestations, particularly inflammatory myositis, are still controversial. This paper aims to assess the correlation between the presence of anti-SSA/Ro52 antibodies and the demographic, clinical and prognosis characteristics of patients with systemic sclerosis (SSc).This is a retrospective, cross-sectional and observational study in patients with SSc. Baseline demographic and clinical characteristics were recorded. Presence of anti-SSA/Ro52, anti-SSA/Ro, anti-SSB/La, snRNP/Sm, anti-centromere, anti-Scl-70 and anti-PM-Scl were analysed by immunoblot, and antinuclear antibodies (ANA) by indirect immunofluorescence. Statistical analysis was performed with PASW Statics 18 software.A total of 132 consecutive patients with analysis of anti-SSA/Ro52 antibodies were selected from a Spanish cohort of 408 patients with SSc, 87.1% of them being women. About half of patients had the limited form (51.5%), followed by diffused form (18.9%), sclerosis sine scleroderma (22.7%), and pre-scleroderma (6.8%). Prevalence of anti-SSA/Ro52 was 35.6%. No association between anti-SSA/Ro52 and clinical manifestations was found, while detection of anti-SSA/Ro52 was significantly associated with the presence of anti-Ro.The results of our study show that anti-SSA/Ro52 antibodies are often found in SSc patients. No clinical manifestations, including inflammatory myopathy, were related with anti-SSA/Ro antibodies.

Published
2014

33. Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models

Author

Doktorova TY, Yildirimman R, Vinken M, Vilardell M, Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, Li R, Chesne C, van Delft J, Kleinjans J, Castell J, Bjorquist P, Herwig R, and Rogiers V

Abstract

As the conventional approach to assess the potential of a chemical to cause cancer in humans still includes the 2-year rodent carcinogenicity bioassay, development of alternative methodologies is needed. In the present study, the transcriptomics responses following exposure to genotoxic (GTX) and non-genotoxic (NGTX) hepatocarcinogens and non-carcinogens (NC) in five liver-based in vitro models, namely conventional and epigenetically stabilized cultures of primary rat hepatocytes, the human hepatoma-derived cell lines HepaRG and HepG2 and human embryonic stem cell-derived hepatocyte-like cells, are examined. For full characterization of the systems, several bioinformatics approaches are employed including gene-based, ConsensusPathDB-based and classification analysis. They provide convincingly similar outcomes, namely that upon exposure to carcinogens, the HepaRG generates a gene classifier (a gene classifier is defined as a selected set of characteristic gene signatures capable of distinguishing GTX, NGTX carcinogens and NC) able to discriminate the GTX carcinogens from the NGTX carcinogens and NC. The other in vitro models also yield cancer-relevant characteristic gene groups for the GTX exposure, but some genes are also deregulated by the NGTX carcinogens and NC. Irrespective of the tested in vitro model, the most uniformly expressed pathways following GTX exposure are the p53 and those that are subsequently induced. The NGTX carcinogens triggered no characteristic cancer-relevant gene profiles in all liver-based in vitro systems. In conclusion, liver-based in vitro models coupled with transcriptomics techniques, especially in the case when the HepaRG cell line is used, represent valuable tools for obtaining insight into the mechanism of action and identification of GTX carcinogens.

Published
2013

34. Oesophageal cancer survival in Europe: A EUROCARE-4 study

Author

Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Go´ z´dz´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo

Subjects
Stage, Adult, Male, Cancer Research, Survival, Adolescent, Esophageal Neoplasms, Epidemiology, Socio-culturale, Subtype, Disease, Europe/epidemiology, Young Adult, Cancer, Europe, Oesophagus, Trends, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Registries, Survival Rate, Oncology, medicine, 80 and over, Young adult, Stage (cooking), cancer survival, Survival rate, ddc:613, Relative survival, business.industry, Oesophageal cancer, Cancer survival, medicine.disease, Esophageal Neoplasms/mortality/pathology, business, Demography, Cohort study
Abstract

Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.

Published
2012

35. Survival of European patients with central nervous system tumors

Author

Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, Børge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Źakelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo

Subjects
Oncology, Ependymoma, Adult, Male, medicine.medical_specialty, Pathology, Cancer Research, Adolescent, Central Nervous System Neoplasms/mortality, Population, survival, NO, Benign tumor, Central Nervous System Neoplasms, Young Adult, Sex Factors, Internal medicine, morphology, medicine, 80 and over, Humans, Registries, Young adult, central nervous system tumors, Europe, Age Factors, Aged, Aged, 80 and over, Female, Middle Aged, Survival Rate, education, Survival rate, ddc:613, Medulloblastoma, education.field_of_study, Relative survival, business.industry, Cancer survival, Cancer, central nervous system tumors, survival, morphology, Europe, medicine.disease, business
Abstract

We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.

Published
2011

36. Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective

Author

Herwig, R., primary, Gmuender, H., additional, Corvi, R., additional, Bloch, K. M., additional, Brandenburg, A., additional, Castell, J., additional, Ceelen, L., additional, Chesne, C., additional, Doktorova, T. Y., additional, Jennen, D., additional, Jennings, P., additional, Limonciel, A., additional, Lock, E. A., additional, McMorrow, T., additional, Phrakonkham, P., additional, Radford, R., additional, Slattery, C., additional, Stierum, R., additional, Vilardell, M., additional, Wittenberger, T., additional, Yildirimman, R., additional, Ryan, M., additional, Rogiers, V., additional, and Kleinjans, J., additional

Published
2015
Full Text
View/download PDF

37. Survival trends in European cancer patients diagnosed from 1988 to 1999

Author

Verdecchia, Arduino, Guzzinati, Stefano, Francisci, Silvia, De Angelis, Roberta, Bray, Freddie, Allemani, Claudia, Tavilla, Andrea, Santaquilani, Mariano, Sant, Milena, Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Survival, MESH : Mortality, MESH : Age Distribution, MESH : Aged, Colonoscopy, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Prostate, Residence Characteristics, Neoplasms, 80 and over, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH: Residence Characteristics, Young adult, cancer survival, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Relative survival, Europe, Population registries, Time trends, Adolescent, Adult, Age Distribution, Aged, Female, Humans, Middle Aged, Mortality, Sex Distribution, Survival Analysis, Young Adult, Oncology, MESH: Sex Distribution, MESH : Adult, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, Rectum, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, Cervix, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Surgery, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; We analysed data from 49 cancer registries in 18 European countries over the period 1988-1999 to delineate time trends in cancer survival. Survival increased in Europe over the study period for all cancer sites that were considered. There were major survival increases in 5 year age-adjusted relative survival for prostate (from 58% to 79%), colon and rectum (from 48% to 54% men and women), and breast (from 74% to 83%). Improvements were also significant for stomach (from 22% to 24%), male larynx (from 62% to 64%), skin melanoma (from 78% to 83%), Hodgkin disease (from 77% to 83%), non-Hodgkin lymphoma (from 49% to 56%), leukaemias (from 37% to 42%), and for all cancers combined (from 34% to 39% in men, and from 52% to 59% in women). Survival did not change significantly for female larynx, lung, cervix or ovary. The largest increases in survival typically occurred in countries with the lowest survival, and contributed to the overall reduction of survival disparities across Europe over the study period. Differences in the extent of PSA testing and mammographic screening, and increasing use of colonoscopy and faecal blood testing together with improving cancer care are probably the major underlying reasons for the improvements in survival for cancers of prostate, breast, colon and rectum. The marked survival improvements in countries with poor survival may indicate that these countries have made efforts to adopt the new diagnostic procedures and the standardised therapeutic protocols in use in more affluent countries.

Published
2009
Full Text
View/download PDF

38. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

Author

De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Cancer Research, MESH: Quality Control, computer.software_genre, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Medicine, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, education.field_of_study, Database, Relative survival, Incidence (epidemiology), Europe, Population registries, Survival analysis, Vital statistics, Databases as Topic, Epidemiologic Methods, Humans, Quality Control, Oncology, MESH : Quality Control, 3. Good health, 030220 oncology & carcinogenesis, Population, MESH : Europe, MEDLINE, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Epidemiologic Methods, 03 medical and health sciences, education, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, Data quality, MESH: Europe, MESH : Databases as Topic, business, computer, MESH: Databases as Topic, International Classification of Diseases for Oncology
Abstract

International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.

Published
2009
Full Text
View/download PDF

39. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary

Author

Sant, Milena, Allemani, Claudia, Santaquilani, Mariano, Knijn, Arnold, Marchesi, Francesca, Capocaccia, Riccardo, Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Epidemiology, Medicine, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH : Sex Distribution, MESH: Aged, MESH: Middle Aged, Relative survival, MESH: Sex Distribution, Population-based cancer registries, Middle Aged, MESH : Adult, Cancer survival, EUROCARE, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Sex Distribution, Survival Analysis, Oncology, 3. Good health, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Skin melanoma, Stage at diagnosis, medicine.medical_specialty, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Age and sex, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, Advanced stage, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, Demography
Abstract

International audience; EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.

Published
2009
Full Text
View/download PDF

40. The cure of cancer: a european perspective

Author

Francisci, Silvia, Capocaccia, Riccardo, Grande, Enrico, Santaquilani, Mariano, Simonetti, Arianna, Allemani, Claudia, Gatta, Gemma, Sant, Milena, Zigon, Giulia, Bray, Freddie, Janssen-Heijnen, Maryska, Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Colorectal cancer, MESH : Age Distribution, MESH : Aged, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Prostate cancer, 0302 clinical medicine, Breast cancer, MESH: Aged, 80 and over, Colon and rectum cancer, Cure, Lung cancer, Relative survival, Statistical models, Stomach cancer, Oncology, Neoplasms, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, Aged, 80 and over, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Middle Aged, MESH : Adult, Prognosis, 3. Good health, Europe, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Young Adult, Age Distribution, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; Cancer survival analyses based on cancer registry data do not provide direct information on the main aim of cancer treatment, the cure of the patient. In fact, classic survival indicators do not distinguish between patients who are cured, and patients who will die of their disease and in whom prolongation of survival is the main objective of treatment. In this study, we applied parametric cure models to the cancer incidence and follow-up data provided by 49 EUROCARE-4 (European Cancer Registry-based study, fourth edition) cancer registries, with the aims of providing additional insights into the survival of European cancer patients diagnosed from 1988 to 1999, and of investigating between-population differences. Between-country estimates the proportion of cured patients varied from about 4-13% for lung cancer, from 9% to 30% for stomach cancer, from 25% to 49% for colon and rectum cancer, and from 55% to 73% for breast cancer. For all cancers combined, estimates varied between 21% and 47% in men, and 38% and 59% in women and were influenced by the distribution of cases by cancer site. Countries with high proportions of cured and long fatal case survival times for all cancers combined were characterised by generally favourable case mix. For the European pool of cases both the proportion of cured and the survival time of fatal cases were associated with age, and increased from the early to the latest diagnosis period. The increases over time in the proportions of Europeans estimated cured of lung, stomach and colon and rectum cancers are noteworthy and suggest genuine progress in cancer control. The proportion of cured of all cancers combined is a useful general indicator of cancer control as it reflects progress in diagnosis and treatment, as well as success in the prevention of rapidly fatal cancers.

Published
2009
Full Text
View/download PDF

41. Long-term survival expectations of cancer patients in Europe in 2000-2002

Author

Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Gerontology, Male, Cancer Research, MESH: Registries, Survival, MESH : Life Expectancy, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Neoplasms, 80 and over, Medicine, Cancer registries, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Registries, Young adult, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Relative survival, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, 3. Good health, Europe, Survival Rate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Period Analysis, Female, cancer survival - long term, MESH: Life Expectancy, Adult, MESH: Survival Rate, Period analysis, Adolescent, Age Distribution, Aged, Humans, Life Expectancy, Survival Analysis, Young Adult, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Life expectancy, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.

Published
2009
Full Text
View/download PDF

42. Comparative cancer survival information in Europe

Author

Berrino, Franco, Verdecchia, Arduino, Lutz, Jean Michel, Lombardo, Claudio, Micheli, Andrea, Capocaccia, Riccardo, Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Genevois des Tumeurs, CHU Genève, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Pathology, medicine.medical_specialty, Cancer Research, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Publications, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Epidemiology of cancer, Medicine, Humans, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Health planning, cancer survival, ComputingMilieux_MISCELLANEOUS, MESH: Humans, business.industry, Health Policy, MESH : Humans, Publications, Cancer survival, MESH : Publications, Descriptive epidemiology, MESH : Neoplasms, Survival Analysis, MESH: Male, 3. Good health, Europe, Female, Oncology, Chronic disease, MESH: Survival Analysis, 030220 oncology & carcinogenesis, MESH: Health Policy, MESH: Europe, MESH : Health Policy, MESH : Survival Analysis, business, MESH: Female, Humanities
Abstract

Franco Berrino*, Arduino Verdecchia, Jean Michel Lutz, Claudio Lombardo, Andrea Micheli, Riccardo Capocaccia, the EUROCARE Working Group Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy National Centre for Epidemiology, Surveillance and Health Promotion, Department of Cancer Epidemiology, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy Department of Chronic Disease Epidemiology, National Institute for Cancer Epidemiology and Registration (NICER), University of Zurich, Sumatrastrasse 30, Zurich, Switzerland Focal Point International Affairs Executive, Alleanza Contro il Cancro, IST Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, Genova, Italy Descriptive Epidemiology and Health Planning Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy

Published
2009
Full Text
View/download PDF

44. Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models

Author

Medicina i Cirurgia, Universitat Rovira i Virgili, Borras, J. M., Izquierdo, A., Freitas, A., Buxo, M., Puigdefabregas, A., Borras, J., Vilardell, M. L., Ameijide, A., Gispert, R., Marcos-Gragera, R., Galceran, J., Cleries, R., Esteban, L., Ribes, J., Medicina i Cirurgia, Universitat Rovira i Virgili, Borras, J. M., Izquierdo, A., Freitas, A., Buxo, M., Puigdefabregas, A., Borras, J., Vilardell, M. L., Ameijide, A., Gispert, R., Marcos-Gragera, R., Galceran, J., Cleries, R., Esteban, L., and Ribes, J.

Abstract

To predict the burden of cancer in Catalonia by 2020 assessing changes in demography and cancer risk during 2010-2020.Data were obtained from Tarragona and Girona cancer registries and Catalan mortality registry. Population age distribution was obtained from the Catalan Institute of Statistics. Predicted cases in Catalonia were estimated through autoregressive Bayesian age-period-cohort models.There will be diagnosed 26,455 incident cases among men and 18,345 among women during 2020, which means an increase of 22.5 and 24.5 % comparing with the cancer incidence figures of 2010. In men, the increase of cases (22.5 %) can be partitioned in three components: 12 % due to ageing, 8 % due to increase in population size and 2 % due to cancer risk. In women, the role of each component was 9, 8 and 8 %, respectively. The increased risk is mainly expected to be observed in tobacco-related tumours among women and in colorectal and liver cancers among men. During 2010-2020 a mortality decline is expected in both sexes.The expected increase of cancer incidence, mainly due to tobacco-related tumours in women and colorectal in men, reinforces the need to strengthen smoking prevention and the expansion of early detection of colorectal cancer in Catalonia.

Published
2014

48. Inkjet printing of multifilamentary YBCO for low AC loss coated conductors

Author

Hopkins, S C, primary, Joseph, D, additional, Mitchell-Williams, T B, additional, Calleja, A, additional, Vlad, V R, additional, Vilardell, M, additional, Ricart, S, additional, Granados, X, additional, Puig, T, additional, Obradors, X, additional, Usoskin, A, additional, Falter, M, additional, Bäcker, M, additional, and Glowacki, B A, additional

Published
2014
Full Text
View/download PDF

49. Cyclosporin and serum lipids in renal transplant recipients

Author

Florian Kronenberg, Luuk B. Hilbrands, Hans Dieplinger, Karl Lhotta, Edwina A. Brown, Gerd Utermann, Vilardell M, Ashley Irish, L.L. Piera, A.T. Webb, P.N.M. Demacker, P. Chacón, A.J. Hoitsma, Alfred Königsrainer, A. Segarra, Paul König, and C. Sandholzer

Subjects
medicine.medical_specialty, Text mining, Renal transplant, business.industry, Internal medicine, medicine, MEDLINE, Blood lipids, General Medicine, medicine.disease, business, Gastroenterology, Kidney transplantation
Published
1993
Full Text
View/download PDF

50. Technetium-99m-HMPAO brain SPECT in Behçet's disease

Author

Amparo Garcia-Burillo, Castell J, Fraile M, Jacas C, Vilardell M, Ortega D, and Ja, Bosch

Subjects
Adult, Male, Tomography, Emission-Computed, Single-Photon, Adolescent, Behcet Syndrome, Brain, Middle Aged, Magnetic Resonance Imaging, Technetium Tc 99m Exametazime, Cerebrovascular Circulation, Humans, Female, Radiopharmaceuticals, Aged
Abstract

Behçet's disease (BD) is an idiopathic multisystem disorder. Involvement of the central nervous system (CNS) occurs in 4%-48% of cases. The aim of this study was to evaluate 99mTc-hexamethyl propyleneamine oxime (HMPAO) SPECT findings in BD patients and eventually to detect CNS involvement by depicting cerebral blood flow disturbances.Technetium-99m-HMPAO brain SPECT was performed on 33 consecutive BD patients. Qualitative and quantitative evaluation of the cortical uptake was done using an automatic program that generated 32 regions of interest (ROIs). An uptake index for each ROI was obtained. Reference values were obtained from a healthy control group (n = 20). Twenty-five patients also had an MRI study.Twelve of 32 patients (36%) presented with a clinical neurological disorder. SPECT and visual evaluation revealed that 17 patients (51.5%) had abnormalities; 9 of 25 MRI studies (36%) were abnormal. Using the quantitative approach for SPECT, 23 patients (69.7%) had abnormally low values. Six of 12 patients with neurological symptoms had a visually abnormal SPECT scan, whereas quantitative analysis showed abnormalities in 11 patients. Of the 21 patients with no neurological findings, 9 had abnormal SPECT results, and 12 had low uptake indexes.HMPAO brain SPECT shows high rates of cerebral blood flow abnormalities in BD patients presenting with neuropsychiatric symptoms, and it also is frequently abnormal in asymptomatic BD patients who have no abnormalities on MR scans. Compared with visual analysis, quantitative analysis detects an even higher rate of SPECT changes in BD patients.

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results